Ahead 300
Overview
The Ahead 300, later commercialized as BrainScope One, is a portable, non-invasive, non-radiation emitting, point-of-care medical device designed to aid clinicians in the rapid and objective assessment of traumatic brain injury (TBI), including concussions and brain bleeds. It utilizes proprietary, patent-protected electroencephalography (EEG) capabilities, advanced signal processing, sophisticated algorithms, and machine learning to analyze head-injured patient data. The device provides a multi-modal assessment, offering a comprehensive panel of data to assist in the diagnosis of the full spectrum of TBI. It is intended for use as an adjunct to standard clinical practice to aid in the evaluation of patients being considered for a head CT, who sustained a closed head injury within 72 hours, present with a Glasgow Coma Scale (GCS) score of 13-15, and are between the ages of 18-85 years. The Ahead 300 helps identify patients likely to have structural brain injury visible on a CT scan and can potentially reduce the number of unnecessary head CT scans in emergency departments.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered EEG analysis for TBI assessment
- Identifies structural brain injuries (brain bleeds)
- Assesses functional brain injuries (concussions)
- Portable, handheld device with disposable electrode headset
- Non-invasive and non-radiation emitting
- Provides rapid, objective assessment at point of care
- Reduces unnecessary head CT scans
- Integrates advanced signal processing and machine learning
- Offers a multi-modal, comprehensive panel of data
- Actionable results downloadable to PDF
Use Cases
- Emergency Departments for TBI evaluation
- Urgent Care Centers for head injury assessment
- Concussion Clinics for objective diagnosis
- Military healthcare system for battlefield TBI assessment
- Sports medicine settings for concussion management
What Physicians Need to Know
The BrainScope Ahead 300 is a valuable point-of-care tool for rapidly and objectively assessing adult patients (18-85 years old, GCS 13-15) with mild head injuries within 72 hours of injury. It aids in determining the likelihood of a structural brain injury requiring a CT scan and provides an objective assessment of concussion severity through its Brain Function Index. This can help reduce unnecessary CT scans, radiation exposure, and emergency department length of stay. It is an adjunct to, not a replacement for, a CT scan. The device's ease of use and rapid results facilitate improved patient triage and management in various settings, including emergency departments, urgent care clinics, and sports environments.
The Ahead 300 is a self-contained, handheld device utilizing a proprietary disposable sensor headset. Its core functionality is delivered directly on the device, leveraging advanced algorithms and machine learning for real-time EEG analysis. While it produces a summary report for sharing, extensive integration with external EMR/EHR systems for automated data transfer or advanced clinical alert systems is not explicitly detailed as a primary feature in the provided information, beyond its ability to provide a digitized, streamlined report. BrainScope's broader platform, however, indicates potential for biomarker application to EEG data from third-party devices via cloud or API.
Details
| Category | Neurology AI, Triage & ER/ICU AI |
| Pricing | Contact for pricing — N/A |
| Deployment | Point-of-care device |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Yes AI-estimated The Ahead 300 received FDA 510(k) clearance (K161068) on September 22, 2016, for use as an adjunct to standard clinical practice to aid in the evaluation of patients with closed head injury. It was the first device in neurology cleared by the FDA under the AI/Machine Learning-Enabled Medical Device category. |
| Integrations | |
| EHR | Not specified |
| Specialties | Emergency Medicine, Neurology, Sports Medicine |
What the Web Says
The BrainScope Ahead 300, also commercialized as BrainScope One, is a portable, non-invasive, non-radiation emitting device designed to aid in the assessment of traumatic brain injury (TBI), including concussions, in patients aged 18-85 who present with mild symptoms within 72 hours of injury. It utilizes EEG technology, advanced algorithms, and machine learning to provide an objective assessment of the likelihood of TBI, including structural injuries visible on a CT scan and mild TBI. The device aims to reduce unnecessary CT scans, radiation exposure, and wait times in emergency departments.
Overall: PositiveStrengths
- Portable and ruggedized for use in various settings, including field, medevac, field hospitals, urgent care, concussion clinics, sports, and military environments.
- Provides rapid and objective assessment of TBI.
- Aids in identifying the likelihood of structural brain injury and functional brain impairment.
- Potential to significantly reduce unnecessary CT scans by up to one-third, decreasing radiation exposure and healthcare costs.
- FDA cleared for clinical use.
- Supported by multiple peer-reviewed publications and clinical trials demonstrating high accuracy.
Limitations
- Not a substitute for a CT scan.
- Primarily tested on adults (18-85 years old), with limited information on efficacy for children and teens.
- Relies on disposable sensor arrays/headsets, incurring ongoing costs.
- Company has not publicly disclosed the cost of the system, though it is stated to be a fraction of a CT scanner.
- One review noted the CEO did not respond to repeated interview requests.
- Older versions of BrainScope technology were primarily for research purposes, with Ahead 300 being the first commercially launched product.
Based on reviews from: Recoil Magazine, Gizmodo, Suzanne Hodsden (via MedTech Intelligence), FDA, Physician Ai Tools, Undark Magazine, The United States Army, Authorea, News-Medical.net, BrainScope (Press Release), Journal of Neurotrauma (via BrainScope), Maryland Daily Record, Regulations.gov, Federal Register
Last updated: 2026-07-17
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Ahead 300
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for Ahead 300.
u092cu094du0930u0947u0928 u0939u0947u092eu0930u0947u091c u0915u093e u0907u0932u093eu091c 1. u0926u0935u093eu0907 2. u0911u092au0930u0947u0936u0928 (Brain Hemorrhage), Dr. Bhaumik Thakor | Neuro Surgeon
Dr. Bhaumik Thakor
